Recipharm forms RecipharmCobra Biologics
Recipharm has combined Cobra Manufacturing with its biologics activities in Sweden.
Recipharm has combined Cobra Manufacturing with its biologics activities in Sweden.
The Swedish contract development and manufacturing organisation (CDMO) acquired UK-based Cobra Biomanufacturing last December and said the move would more than double its biologics offering.
The integrated business will now be known as RecipharmCobra Biologics and will operate as Recipharm's specialist biologics division.
The combination of both companies" capabilities creates a full biological service offering, encompassing cell line development, analytical and process development and GMP production of recombinant proteins, DNA, viruses and cell products for Phase I, II and III clinical trials. The company says this, together with fill-finish and formulation capabilities, has created a one-stop shop for all biologics outsourcing needs.
Simon Saxby, former chief executive of Cobra Biomanufacturing, will head RecipharmCobra Biologics in the newly created role of vice president, Biologics.
With the integration complete, RecipharmCobra Biologics will have cGMP approved production facilities in Keele and Oxford in the UK and Soedertaelje in Sweden.
RecipharmCobra Biologics holds IP and licences in expression technologies, including ORT-VAC and UCOE.
"Integrating the experience of Cobra Biomanufacturing's staff, expertise and established services with our own previous offering has, we believe, created a much stronger force in the industry's biologics outsourcing sector," said Thomas Eldered, chief executive of Recipharm.
"Indeed, in addition to antibodies and rProteins, our integrated company competitively offers both process development and cGMP manufacturing services for viruses, DNA and cells."
He added: "The move will also further build our position as a leading CDMO that provides a full range of high-quality services."
